Genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population

Year 2019, Volume: 23 Issue: 6, 1149 - 1156, 27.06.2025

Zuhal Uçkun Şahinoğulları , Necmiye Canacankatan , Mehmet Canacankatan

Abstract

Many xenobiotic and endogenous compounds are transported from blood into hepatocytes mediated by organic anion transporter protein (OATP1B1), which is encoded by solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene. Genetic polymorphisms in SLCO1B1 gene can affect in pharmacokinetics of most compounds and may cause changes in drug efficacy and advers reactions. Thus, genetic polymorphism analysis of genes that may affect the pharmacokinetics of compounds is extremely important. The goal of this study was to determine the genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population and also to compare our results with the findings of other previously reported populations. Genotyping analyses of SLCO1B1 g.89595 T>C polymorphism was carried out in 68 healthy Turkish volunteers by a polymerase chain reaction restriction fragment length polymorphism method. The frequencies of the TT, TC, and CC genotypes were 77.9, 19.1 and 3.0, respectively. Also, the frequencies of T and C alleles were 87.5 and 12.5, respectively. The genotype frequencies were consistent with Hardy–Weinberg equilibrium. The results of the study are compared with those of other ethnic groups, and they displayed pronounced ethnic group differences, especially East Asian and Southeast ancestry. The detection of SLCO1B1 polymorphisms may ensure benefits for adjustment of dosage regimens of some drugs and protecting from and/or decreasing adverse events, and also for future studies concerning SLCO1B1 transporter and its polymorphisms.

Keywords

SLCO1B1 , drug transporter , genetic polymorphism , Turkish population

References

• [1] Ma Q, Lu AY. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol Rev. 2011; 63(2): 437-459. [CrossRef]
• [2] Jin T, Aikemu A, Zhang M, Geng T, Feng T, Kang L, Luo ML. Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. Med Sci Monit. 2015; 21: 3769-3776. [CrossRef]
• [3] Uckun Z, Baskak B, Ozdemir H, Ozel-Kizil ET, Devrimci-Ozguven H, Suzen HS. Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish patients with major depressive disorder. Turk J Pharm Sci. 2018; 15(2): 200-206. [CrossRef]
• [4] Nagy A, Sipeky C, Szalai R, Melegh BI, Matyas P, Ganczer A, Toth K, Melegh B. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations. BMC Genet. 2015; 16: 108. [CrossRef]
• [5] Kaewboonlert N, Thitisopee W, Sirintronsopon W, Porntadavity S, Jeenduang N. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. J Clin Pharm Ther. 2018; 43(5): 647-655. [CrossRef]
• [6] Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010; 20(3): 211–216. [CrossRef]
• [7] Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011; 63(1): 157-181. [CrossRef]
• [8] Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007; 8(7): 787–802. [CrossRef]
• [9] Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol. 2007; 18(4): 409–414.
• [10] Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol. 2008; 64(3): 257-266. [CrossRef]
• [11] Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population. Amerindians as a high risk ethnic group. BMC Med Genet. 2011; 12: 136. [CrossRef]
• [12] Hapmap Project. http://hapmap.ncbi.nlm.nih.gov/ (accessed July 13, 2019).
• [13] Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 2015; 21: 1454-1459. [CrossRef]
• [14] Francesca Notarangelo M, Marziliano N, Antonietta Demola M, Pigazzani F, Guidorossi A, Angelica Merlini P, Ardissino D. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther. 2012; 37(5): 604-606. [CrossRef]
• [15] Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of statin intolerance in 2018: Still more questions than answers. Am J Cardiovasc Drugs. 2018; 18(3): 157-173. [CrossRef]
• [16] Dendramis G. Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. G Ital Cardiol (Rome). 2011; 12(3): 182-185.